Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Valeant’s Higher Bid Seals The Deal With Salix, Ending Endo’s Quest

This article was originally published in The Pink Sheet Daily

Executive Summary

Valeant raised its offer to buy the GI specialist from $158 to $173 per share in cash; Salix’s board of directors accepted the revised offer, ending a bid by Endo to buy the company.

You may also be interested in...



Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny

The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.

Valeant’s Oral Relistor Poised To Face-Off Against AstraZeneca’s Movantik

FDA approval of the first oral form of Valeant’s mu-opioid receptor antagonist Relistor will pit the franchise against Movantik for the treatment of patients with opioid-induced constipation with non-cancer pain.

Rocket Fires Up CV Gene Therapy Pipeline With Renovacor Merger

Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS078266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel